777-P: Efficacy of SGLT2 Inhibitors and GLP1-Receptor Agonists in Asians with Type 2 Diabetes: A Systemic Review and Meta-analysis

Autor: Neda Laiteerapong, Wen Wan, Alexandra C. Knitter, Jason T. Alexander, Melissa Franco, Ryan Johnson, Erin M. Staab
Rok vydání: 2021
Předmět:
Zdroj: Diabetes. 70
ISSN: 1939-327X
0012-1797
DOI: 10.2337/db21-777-p
Popis: Background: Clinical trials of SGLT2Is and GLP1RAs have shown improved outcomes in patients with type 2 diabetes, but comprehensive data of their effectiveness in the Asian subpopulation are lacking. A systematic review and meta-analysis of clinical trials evaluating SGLT2Is and GLP1RAs was conducted to assess their efficacy in Asians with type 2 diabetes. Methods: PubMed, Scopus, and clinicaltrials.gov were searched from inception to July 2019 for randomized controlled trials (≥52 weeks) that enrolled Asians with type 2 diabetes and reported outcome data for SGLT2Is or GLP1RAs compared to placebo or other diabetic medications. Using random effect models, binary outcomes were evaluated with relative risks (RR) and continuous outcomes were evaluated with standardized mean differences (MD). Results: The analysis included 9 trials for SGLT2Is and 11 trials for GLP1RAs. Compared to placebo, SGLT2Is reduced HbA1c (MD: -0.70%, 95% CI: -1.29% to -0.10%) and weight (MD: -1.52 kg, -2.08 to -0.96 kg); compared to other diabetic medications, SGLT2Is reduced systolic blood pressure (MD: -6.42 mmHg, -9.43 to -3.41 mmHg). Compared to placebo, SGLT2Is increased the risk of genital infection (RR: 2.51, 1.01 to 6.21) but reduced the risk for renal events (RR: 0.69, 0.57 to 0.84). GLP1RAs were associated with lower HbA1c (MD: -0.65%, -1.07% to -0.22%) and weight (MD: -2.06 kg, -3.20 to -0.93 kg) when compared to other diabetic medications. GLP1RAs also reduced major cardiovascular events compared to placebo (RR: 0.72, 0.59 to 0.89). Data were not available for comparisons between GLP1RAs and placebo for other outcomes. Neither SGLT2Is or GLP1RAs had sufficient evidence to suggest their use was associated with a change in all-cause mortality. Conclusion: In the Asian subpopulation, clinical trials provide evidence for a reduction in cardiovascular risk factors and some diabetes-related adverse events by SGLT2Is and GLP1RAs. Disclosure R. Johnson: None. M. Franco: None. E. M. Staab: None. A. C. Knitter: None. W. Wan: None. J. Alexander: None. N. Laiteerapong: Other Relationship; Self; American Diabetes Association. Funding American Diabetes Association (1-18-JDF-037 to N.L.)
Databáze: OpenAIRE
Externí odkaz: